SCHEMBL2555802

SCHEMBL2555802

NC(=O)C1CCN(c2nc(-c3ccc(F)cc3)cs2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 15/20 1.00
RAB9A P51151 10/20 1.00
NPC1 O15118 8/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
MEN1 O00255 1/20 0.78
KMT2A Q03164 1/20 0.78
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
GAA P10253 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
ALDH1A1 P00352 1/20 0.65
MAPK1 P28482 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554100 0.89 SMN1; SMN2 (0.80) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2555807 0.88 SMN1; SMN2 (0.78) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2557908 0.88 SMN1; SMN2 (1.00) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2553764 0.88 SMN1; SMN2 (1.00) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2553528 0.88 SMN1; SMN2 (0.83) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2554297 0.88 SMN1; SMN2 (0.78) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL12291571 0.88 SMN1; SMN2 (0.78) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2560046 0.87 SMN1; SMN2 (0.77) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2557828 0.86 SMN1; SMN2 (0.77) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1
SCHEMBL2560040 0.86 SMN1; SMN2 (0.79) SMN1; SMN2RAB9ANPC1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US claimed
WO-2011130515-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-10-20 WO claimed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
WO-2011130515-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SMN1; SMN2, MTPN, MORF4L1 SMN1; SMN2 1/4885RAB9A 1682/4885NPC1 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.